SI
CYT

Sofinnova Investments’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Sofinnova Investments’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-179,450
Closed -$2.04M – 82
2021
Q4 		$2.04M Sell
179,450
-66,871
-27% -$1.02M 0.12% 62
2021
Q3 		$4.32M Sell
246,321
-18,679
-7% -$349K 0.26% 59
2021
Q2 		$5.67M Buy
+265,000
New +$4.96M 0.33% 47

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sofinnova Investments's CYT Position: Q1 2022 in Review

Sofinnova Investments sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2022, closing a stake of 179,450 shares — an estimated $2.04M sold.

Sofinnova Investments first reported a position in CYT in Q2 2021 and held it in 3 quarters. The position peaked at $5.67M in Q2 2021. 52 funds tracked by Wall St. Rank hold CYT as of Q1 2022.

  • Sofinnova Investments reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Sofinnova Investments sold 179,450 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $2.04M.
  • Sofinnova Investments first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Sofinnova Investments's Cyteir Therapeutics, Inc. Common Stock position peaked at $5.67M in Q2 2021.
  • 52 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Sofinnova Investments's 13F filing for Q1 2022, filed 16 May 2022.